ALGS Q2 2021 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$30M-1913.6% margin

Net Income

-$30M-1930.0% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

+69.8%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$212M

Total Liabilities

$43M

Stockholders' Equity

$169M

Cash & Equivalents

$188M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$30M	-$21M	-39.0%
Net Income	-$30M	-$21M	-43.4%